ƽ

ImmunoCult™ Human CD3/CD28 T Cell Activator

cGMP, human T cell activation and expansion reagent

ImmunoCult™ Human CD3/CD28 T Cell Activator

cGMP, human T cell activation and expansion reagent

Catalog #
(Select a product)
cGMP, human T cell activation and expansion reagent
Request Pricing

Product Advantages

  • Activate T cells with confidence for use in clinical applications using activators produced under relevant cGMPs
  • Achieve robust activation without the use of magnetic beads, feeder cells, or antigens
  • Maintain a high viability of activated and expanded T cells with gentle activation stimulus
  • Rely on a highly stable, filter-sterilized soluble reagent

Overview

Achieve robust activation and expansion of human T cells for use in clinical applications–without the use of magnetic beads, feeder cells, or antigens.

This product’s gentle activation stimulus ensures a high viability of activated T cells, which can be further expanded in ܲԴǰܱ™-ݹ—a high-performance T cell expansion medium manufactured under relevant cGMP regulations and guidelines. ImmunoCult™ Human CD3/CD28 T Cell Activator consists of soluble antibody complexes that bind to and cross-link CD3 and CD28 cell surface ligands, thereby providing the required primary and co-stimulatory signals for T cell culture and activation.

ImmunoCult™ Human CD3/CD28 T Cell Activator is designed for cell therapy clinical research applications by qualifying it for use as an ancillary material (AM) following the framework outlined in USP<1043> and/or PH. EUR. 5.2.12. ƽ can work with you to qualify this reagent as an AM under an approved Investigational New Drug (IND) application, Biological Licensing Application (BLA), or Clinical Trial Application (CTA). Learn more about how we can support your regulatory needs here.
Contains
• Anti-human CD3 monospecific antibody complex
• Anti-human CD28 monospecific antibody complex
• Phosphate buffered-saline (PBS), containing 0.02% TWEEN® 20
Subtype
Supplements
Cell Type
T Cells, T Cells, CD4+, T Cells, CD8+
Species
Human
Application
Activation, Cell Culture, Expansion
Brand
ImmunoCult
Area of Interest
Cancer, Immunology, Cell Therapy Development

Data Figures

Activated human T cells clustering together.

Figure 1. Morphology of Activated Human T Cells Stimulated with ImmunoCult™ Human CD3/CD28 T Cell Activator

A clustered morphology is seen in activated human T cells. Cells were isolated using EasySep™ Human T Cell Isolation Kit, stimulated with ImmunoCult™ Human CD3/CD28 T Cell Activator for 3 days in ܲԴǰܱ™-ݹ supplemented with recombinant human interleukin-2 (rhIL-2).

Flow cytometry data showing human T cell activation assessed by CD25 expression.

Figure 2. Activation of Human T Cells Stimulated with ImmunoCult™ Human CD3/CD28 Activator.

Human T cells were stimulated with ImmunoCult™ Human CD3/CD28 T Cell Activator and cultured in ܲԴǰܱ™-ݹ . Activation of viable CD4+ and CD8+ T cells were assessed by CD25 expression, using flow cytometry. Following 3 days of culture, the frequency of CD25-positive cells was (A) 75.5% for CD4+ T cells and (B) 65.3% for CD8+ T cells . The gray line depicts day 3 CD4+ and CD8+ T cells cultured without ImmunoCult™ Human CD3/CD28 T Cell Activator.

Human T cell cumulative fold expansion and activation during a 12-day culture period.

Figure 3. Robust Human T Cell Expansion and High Viability Achieved Using ImmunoCult™ Human CD3/CD28 T Cell Activator

Human T cells were expanded over 12 days with ImmunoCult™ Human CD3/CD28 T Cell Activator in ܲԴǰܱ™-ݹ supplemented with rhIL-2. On day 0, 1 x 10^6 isolated human T cells were stimulated with 25 μL of ImmunoCult™ Human CD3/CD28 T Cell Activator in ܲԴǰܱ™-ݹ supplemented rhIL-2. No additional ImmunoCult™ Human CD3/CD28 T Cell Activator was added during the 12-day culture period (mean ± SD in 3 experiments with 7 donors).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Name
Catalog #
100-0784
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-0784
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (2)

Th17 cell-derived miR-155-5p modulates interleukin-17 and suppressor of cytokines signaling 1 expression during the progression of systemic sclerosis. L. Han et al. Journal of clinical laboratory analysis 2022 jun

Abstract

BACKGROUND miR-155-5p is associated with autoimmune diseases. T helper 17 (Th17) cells, interleukin (IL)-17, and suppressor of cytokines signaling 1 (SOCS1) have important roles in the pathogenesis of systemic sclerosis (SSc). The purpose of this study was to explore the role of miR-155-5p in the regulation of IL-17 and SOCS1 expression in Th17 cells and the subsequent effect on SSc disease progression. METHODS Th17 cells were isolated from peripheral blood mononuclear cells of SSc patients and healthy controls (HCs). RT-qPCR and western blotting were used to examine the expression patterns of miR-155-5p, IL-17, and SOCS1. Luciferase reporter assays were performed to confirm SOCS1 as a target of miR-155-5p. RNA pull-down assays were performed to detect the interaction of IL-17 and SOCS1 with miR-155-5p. In situ hybridization was performed to analyze the co-expression pattern of miR-155-5p and IL17A in Th17 cells. RESULTS The levels of Th17 cell-derived miR-155-5p were significantly up-regulated in SSc patients compared with HCs, and its levels were negatively correlated with SOCS1 levels. Meanwhile, miR-155-5p positively regulated IL-17 expression levels in Th17 cells isolated from SSc patients as the disease progressed. Using pmirGLO vectors, SOCS1 was confirmed as a target of miR-155-5p. The binding status of IL-17 and SOCS1 to miR-155-5p was related to SSc progression. An increase in the co-localization of miR-155-5p and IL-17 was associated with greater SSc progression. CONCLUSIONS IL-17 and SOCS1 expression modulated by Th17 cell-derived miR-155-5p are critical for SSc progression, which may provide novel insights into the pathogenesis of SSc.
Stress hormone signalling inhibits Th1 polarization in a CD4 T-cell-intrinsic manner via mTORC1 and the circadian gene PER1. C. M. Capelle et al. Immunology 2022 apr

Abstract

Stress hormones are believed to skew the CD4 T-cell differentiation towards a Th2 response via a T-cell-extrinsic mechanism. Using isolated primary human na{\{i}}ve and memory CD4 T cells here we show that both adrenergic- and glucocorticoid-mediated stress signalling pathways play a CD4 na{\"{i}}ve T-cell-intrinsic role in regulating the Th1/Th2 differentiation balance. Both stress hormones reduced the Th1 programme and cytokine production by inhibiting mTORC1 signalling via two parallel mechanisms. Stress hormone signalling inhibited mTORC1 in na{\"{i}}ve CD4 T cells (1) by affecting the PI3K/AKT pathway and (2) by regulating the expression of the circadian rhythm gene period circadian regulator 1 (PER1). Both stress hormones induced the expression of PER1 which inhibited mTORC1 signalling thus reducing Th1 differentiation. This previously unrecognized cell-autonomous mechanism connects stress hormone signalling with CD4 T-cell differentiation via mTORC1 and a specific circadian clock gene namely PER1."